Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

被引：63
|
作者：
Carpentier, AF [1 ]
Bonnet, AM [1 ]
Vidailhet, M [1 ]
Agid, Y [1 ]
机构：
[1] FED NEUROL, PARIS, FRANCE
来源：
NEUROLOGY | 1996年 / 46卷 / 06期
关键词：
D O I：
10.1212/WNL.46.6.1548
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment. There was a significant 40% improvement in the dyskinesia. score without increase of parkinsonian motor disability. Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not. This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.
引用
收藏
页码：1548 / 1551
页数：4
相关论文
共 50 条
  • [41] Nigral Iron Deposition Is Associated With Levodopa-Induced Dyskinesia in Parkinson's Disease
    Song, Tianbin
    Li, Jiping
    Mei, Shanshan
    Jia, Xiaofei
    Yang, Hongwei
    Ye, Yongquan
    Yuan, Jianmin
    Zhang, Yuqing
    Lu, Jie
    FRONTIERS IN NEUROSCIENCE, 2021, 15
  • [42] Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
    Schaeffer, Eva
    Pilotto, Andrea
    Berg, Daniela
    CNS DRUGS, 2014, 28 (12) : 1155 - 1184
  • [43] Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease
    Fraix, V
    Pollak, P
    Van Blercom, N
    Xie, J
    Krack, P
    Koudsie, A
    Benabid, AL
    NEUROLOGY, 2001, 57 (10) : S60 - S62
  • [44] Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease
    Ivanova, S. A.
    Alifirova, V. M.
    Freidin, M. B.
    Pozhidaev, I. V.
    Fedorenko, O. Y.
    Bokhan, N. A.
    Zhukova, I. A.
    Zhukova, N. G.
    Wilffert, B.
    Loonen, A. J. M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S1039 - S1040
  • [45] Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
    Eva Schaeffer
    Andrea Pilotto
    Daniela Berg
    CNS Drugs, 2014, 28 : 1155 - 1184
  • [46] Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease
    Fraix, V
    Pollak, P
    Van Blercom, N
    Xie, J
    Krack, P
    Koudsie, A
    Benabid, AL
    NEUROLOGY, 2000, 55 (12) : 1921 - 1923
  • [47] Pathophysiology of levodopa-induced dyskinesia in Parkinson's disease: Opportunities for novel treatments
    Bezard, Erwan
    BEHAVIOURAL PHARMACOLOGY, 2006, 17 (5-6): : 535 - 535
  • [48] White matter hyperintensities and risk of levodopa-induced dyskinesia in Parkinson's disease
    Chung, Seok Jong
    Yoo, Han Soo
    Lee, Yang Hyun
    Jung, Jin Ho
    Baik, KyoungWon
    Ye, Byoung Seok
    Sohn, Young H.
    Lee, Phil Hyu
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2020, 7 (02): : 229 - 238
  • [49] Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease
    Kobylecki, Christopher
    Burn, David J.
    Kass-Iliyya, Lewis
    Kellett, Mark W.
    Crossman, Alan R.
    Silverdale, Monty A.
    PARKINSONISM & RELATED DISORDERS, 2014, 20 (04) : 452 - 455
  • [50] Risk factors for levodopa-induced dyskinesia in Serbian Parkinson's disease patients
    Markovic, V.
    Djuric, G.
    Pekmezovic, T.
    Kostic, V.
    Svetel, M.
    MOVEMENT DISORDERS, 2013, 28 : S317 - S317
12345